Biogen (BIIB) Capital Expenditures (2009 - 2026)

Biogen has reported Capital Expenditures for 18 years, with the latest figure at $40.9 million in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 53.76% year-over-year to $40.9 million in Q2 2026; TTM through Jun 2026 was $182.2 million, a 32.03% increase from a year earlier, with the FY2025 full-year figure at $153.8 million, changed 0.07% from the prior year.
• Capital Expenditures was $40.9 million for Q2 2026 at Biogen, down from $51.2 million in the prior quarter.
• The five-year high for Capital Expenditures was $86.4 million in Q4 2022, with the low at $26.6 million in Q2 2025.
• Average Capital Expenditures over 5 years is $50.9 million, with a median of $46.0 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures soared 92.41% in 2023, then sank 52.83% in 2024.
• Over 5 years, Capital Expenditures stood at $86.4 million in 2022, then fell by 24.54% to $65.2 million in 2023, then plunged by 39.72% to $39.3 million in 2024, then rose by 11.7% to $43.9 million in 2025, then dropped by 6.83% to $40.9 million in 2026.
• The last three Capital Expenditures figures came in at $40.9 million (Q2 2026), $51.2 million (Q1 2026), and $43.9 million (Q4 2025), per Business Quant data.